On January 21, 2026, Joseph E. Gilliam, who serves as President and Chief Operating Officer of Glaukos Corporation (NASDAQ:GKOS), executed sales of 4,502 shares of the company’s common stock. The sales were completed through various transactions at prices ranging from $124.47 to $124.75 per share, resulting in total proceeds of approximately $561,174.
Simultaneously, Gilliam exercised stock options to purchase 4,502 shares at an exercise price of $55.18 per share, bringing the total value of options exercised to around $248,420. These transactions were officially disclosed via a Form 4 filing submitted to the Securities and Exchange Commission.
Following these activities, Gilliam’s direct holdings in Glaukos amount to 92,366 shares. Included in this total are 62,605 restricted stock units that remain unvested. Both the sale of shares and the exercise of options were conducted under a pre-established Rule 10b5-1 trading plan adopted on June 11, 2025, ensuring adherence to regulatory guidelines.
In related corporate developments, Glaukos reported preliminary revenue figures for the fourth quarter of 2025 reaching approximately $143 million. This represents a 36% increase over the prior year’s corresponding period and exceeds analysts’ consensus estimate of $129.4 million.
Detailed segment results highlighted U.S. glaucoma sales generating $86 million, surpassing expectations by roughly 5%. Revenues from the company’s iDose product aligned with forecasted figures. International glaucoma sales reached approximately $33 million, outperforming analyst estimates by 6%. In addition, sales from the Corneal Health segment contributed around $24 million to the quarter’s results.
For the full fiscal year 2025, Glaukos anticipates total net sales near $507 million, reflecting an increase of 32 percent relative to the previous year.
Analyst responses to these results have been positive. Stifel raised its price target on Glaukos shares from $115 to $160 and maintained a Buy rating, noting encouraging feedback from surveys on the Epioxa product. Piper Sandler upheld its Overweight rating and a price target of $165, citing strong Q4 performance across all business areas. UBS also reiterated its Buy rating despite recent stock price declines.
These developments demonstrate sustained market and analyst confidence in Glaukos’s revenue growth and product portfolio amid ongoing industry dynamics.